Friday, July 10, 2026

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo

Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Clinical program

YO45758

Phase 1 · other · Advanced Solid Tumors Harboring RAS Mutation(S)

YO45758 for Advanced Solid Tumors Harboring RAS Mutation(S) is a Phase 1 program (other) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

Internal code YO45758

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hoffmann-La Roche
Phase
Phase 1
Modality
other
Indication
Advanced Solid Tumors Harboring RAS Mutation(S)
Status
active
Trials
1

Clinical trials